Myriad Genetics, Inc. (MYGN) To Sell Prenatal Health Unit To Labcorp For $210M Cash

Myriad Genetics (MYGN) will sell its Prenatal Health unit to Labcorp for $210M in cash, plus inventory value. The deal is subject to regulatory approval and expected to close by early 2027. Myriad aims to focus on cancer diagnostics, while Labcorp expands its testing services.

Original reporting
Published Oct 20, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Myriad Genetics, Inc. (MYGN) To Sell Prenatal Health Unit To Labcorp For $210M Cash — source image
Decision brief

The 30-second read

$MYGNBearishHigh
01

Why it matters

The transaction provides immediate cash to Myriad while expanding Labcorp's test menu, potentially reshaping competitive dynamics.

02

Market read

First report of a $210M divestiture that could move both stocks.

03

What to watch

Regulatory clearance risk and integration costs for Labcorp may temper upside.

Relevance 8/10Novelty 9/10Timing: immediate

Background

Myriad Genetics is refocusing on cancer diagnostics; Labcorp seeks to broaden its specialty testing suite.

Company-level read

Ticker impact

$MYGNBearishHigh confidence
Context

Myriad Genetics announced it will sell its Prenatal Health unit to Labcorp for $210M cash.

Expected impact

likely downward pressure as investors price in loss of revenue from the unit

Evidence & confidence

The cash deal removes a business segment; market typically reacts negatively to asset sales without clear accretion guidance.

$LHBullishHigh confidence
Context

Labcorp agreed to acquire Myriad's Prenatal Health testing business for $210M cash.

Expected impact

potential upside as the market values the added testing capabilities

Evidence & confidence

Strategic fit and cash purchase may be seen as accretive, supporting a modest price lift.

Market effects

Strengthens the specialty diagnostics sector, may boost peers.

U.S. healthcare market sees consolidation activity.

Limited to U.S. biotech and diagnostics investors.

Counterpoint

The sale could signal Myriad's focus shift away from growth areas, hurting long-term prospects.

Key entities

  • Myriad Genetics, Inc.

    Seller of the Prenatal Health unit.

  • Labcorp

    Buyer acquiring the Prenatal Health unit.

Related articles

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

$LHMed

Labcorp Finalizes Acquisition of Millennium Health to Expand Toxicology Testing

Labcorp has completed its acquisition of Millennium Health, a specialty lab focused on drug testing and surveillance. The deal aims to expand Labcorp's toxicology testing capabilities nationwide, providing insights for treating chronic pain, substance use disorders, and mental health conditions. Labcorp expects to integrate Millennium's expertise with its own network and digital solutions to improve patient care.